|
Colorectal Carcinoma
|
0.450 |
AlteredExpression
|
disease |
BEFREE |
Furthermore, overexpression of DLC-1 and RUNX3 revealed antitumor effects in CRC cell lines with the inhibition of cell proliferation, migration and invasion, and the induction of cell apoptosis.
|
30362160 |
2019 |
|
Colorectal Carcinoma
|
0.450 |
Biomarker
|
disease |
BEFREE |
IGF2-derived miR-483 mediated oncofunction by suppressing DLC-1 and associated with colorectal cancer.
|
27366946 |
2016 |
|
Colorectal Carcinoma
|
0.450 |
AlteredExpression
|
disease |
BEFREE |
Conversely, reduced DLC1 expression predominated in lung squamous cell carcinoma (LSC), lung adenocarcinoma (LAD), breast cancer, and hepatocellular carcinoma (HCC), but not in colorectal cancer.
|
27174913 |
2016 |
|
Colorectal Carcinoma
|
0.450 |
Biomarker
|
disease |
BEFREE |
Moreover, we identify DLC1 as a direct target of miR-106b, reveal its expression to be inversely correlated with miR-106b in CRC samples and show that its re-introduction reverses miR-106b-induced CRC cell migration and invasion.
|
26223867 |
2015 |
|
Colorectal Carcinoma
|
0.450 |
GeneticVariation
|
disease |
BEFREE |
Partial (1%-10%) and extensive (10%-100%) DLC-1 promoter methylations were observed in 10% and 0% of normal mucosa, 46% and 14% of adenomas, and 60% and 36% of CRCs, respectively.
|
23509688 |
2013 |
|
Colorectal Carcinoma
|
0.450 |
CausalMutation
|
disease |
CLINVAR |
|
|
|
|
Colorectal Carcinoma
|
0.450 |
Biomarker
|
disease |
CTD_human |
|
|
|
|
Stomach Neoplasms
|
0.410 |
Therapeutic
|
group |
CTD_human |
Genomic alterations in BCL2L1 and DLC1 contribute to drug sensitivity in gastric cancer.
|
26401016 |
2015 |
|
Stomach Neoplasms
|
0.410 |
PosttranslationalModification
|
group |
LHGDN |
Transcriptional silencing of the DLC-1 tumor suppressor gene by epigenetic mechanism in gastric cancer cells.
|
12813468 |
2003 |
|
Stomach Neoplasms
|
0.410 |
Biomarker
|
group |
HPO |
|
|
|
|
Malignant Neoplasms
|
0.400 |
AlteredExpression
|
group |
BEFREE |
In addition, we explore the clinical data of DLC1 and the mechanisms that natural products upregulate the DLC1 expression to inhibit cancer.
|
31773748 |
2020 |
|
Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
Importantly, when fused to the tat protein-transduction sequence and subsequently introduced into cells, the C2 peptides potently promoted the RhoGAP function in DLC1, leading to decreased RhoA activation and reduced tumor cell growth in soft agar and migration in response to growth factor stimulation.
|
31806702 |
2020 |
|
Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
A tumor suppressor DLC1: The functions and signal pathways.
|
31773748 |
2020 |
|
Malignant Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
Deleted in Liver Cancer 1 (DLC1) is a tumor suppressor gene deleted in many cancers, including angiosarcoma, an aggressive malignancy of endothelial cell derivation.
|
31409902 |
2019 |
|
Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
DLC1 was also identified as an estrogen-induced tumor suppressor in the normal mammary gland with decreased expression in breast cancer.
|
31110002 |
2019 |
|
Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
Tripathi investigates how the tumor suppressor DLC1 is regulated by oncogenic kinases.
|
31515239 |
2019 |
|
Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
Together, these findings indicate cooperation between the SRC, ERK1/2, and AKT kinases to reduce DLC1 Rho-GAP and tumor suppressor activities in cancer cells, which can be reactivated by the kinase inhibitors.
|
31308216 |
2019 |
|
Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
Deleted in Liver Cancer 1 (DLC1) is a tumor suppressor gene deleted in many cancers, including angiosarcoma, an aggressive malignancy of endothelial cell derivation.
|
31409902 |
2019 |
|
Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
So far, the role of the first identified member from the DLC family, DLC1, was established as a tumor suppressor in hepatocellular carcinoma.
|
30827083 |
2019 |
|
Malignant Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
However, DLC1 is not known to be deleted in angiosarcoma, an aggressive malignancy of endothelial cell derivation.
|
29202196 |
2018 |
|
Malignant Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
This study was designed to investigate the biological role of DLC1 in resveratrol induced cancer cellular senescence.
|
29964052 |
2018 |
|
Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
The tumor suppressor DLC1 inhibits cancer progression and oncogenic autophagy in hepatocellular carcinoma.
|
29785050 |
2018 |
|
Neoplasms
|
0.400 |
AlteredExpression
|
group |
BEFREE |
The findings indicate: 1) C3R (25 μM) has the potential to reduce RKO cell motility in vitro; 2) ingestion of lyophilized AP reduces the total number of aberrant crypt foci (ACF), ACF multiplicity, tumor cell proliferation and incidence of tumors with high grade dysplasia; 3) AP increases the gene expression of negative regulators of cell proliferation such as Dlc1 and Akt3, as well as inflammation (Ppara).
|
30194994 |
2018 |
|
Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
Tumor suppressor gene DLC1 is shown to induce apoptosis, suppress migration and invasion in various cancer cells.
|
29964052 |
2018 |
|
Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
Quantitative phosphoproteomic analysis identifies novel functional pathways of tumor suppressor DLC1 in estrogen receptor positive breast cancer.
|
30278072 |
2018 |